Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom.
The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis.
The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 14, 24 | -0.06 Increased by +95.80% | -0.06 |
| Mar 12, 24 | -0.04 Increased by +42.86% | - |
| Jan 9, 24 | -0.03 Increased by +78.57% | - |
| Aug 9, 23 | -0.02 Increased by +88.24% | - |
| May 11, 23 | -1.43 Decreased by -550.00% | - |
| Mar 9, 23 | -0.07 Increased by +75.00% | -0.26 Increased by +73.08% |
| Nov 9, 22 | -0.14 Increased by +86.00% | -0.26 Increased by +46.15% |
| Aug 11, 22 | -0.17 Increased by +87.41% | -0.27 Increased by +37.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Oct 31, 23 | N/A Decreased by -100.00% | -21.27 M Increased by +17.66% | - - |
| Jul 31, 23 | 235.00 K Increased by 0.00% | -14.72 M Increased by +29.41% | Decreased by -6.26 K% Increased by +29.41% |
| Apr 30, 23 | 0.00 Decreased by -100.00% | -1.58 B Decreased by -7.56 K% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 23 | 705.00 Decreased by -99.72% | -16.32 M Increased by +39.76% | Decreased by -2.32 M% Decreased by -21.35 K% |
| Oct 31, 22 | 220.00 K Decreased by -83.19% | -25.83 M Decreased by -31.79% | Decreased by -11.74 K% Decreased by -684.17% |
| Jul 31, 22 | 235.00 K Increased by +312.28% | -20.85 M Increased by +14.61% | Decreased by -8.87 K% Increased by +79.29% |
| Apr 30, 22 | 250.00 K Increased by +30.21% | -20.64 M Decreased by -18.00% | Decreased by -8.25 K% Increased by +9.38% |
| Jan 31, 22 | 251.00 K Increased by +35.68% | -27.10 M Decreased by -100.13% | Decreased by -10.80 K% Decreased by -47.50% |